Literature DB >> 11397648

Diabetes mellitus and diabetes-associated vascular disease.

D Kirpichnikov1, J R Sowers.   

Abstract

Diabetes-related cardiovascular disease remains the leading cause of death in patients with type 2 diabetes. Hypertension is common among diabetics and has the same pathogenetic mechanisms as insulin resistance, in which the activated renin-angiotensin system contributes to the emerging high blood pressure and hyperglycemia. Hyperglycemia is one of the triggering factors for vascular dysfunction and clotting abnormalities and, therefore, for accelerated atherosclerosis in diabetes. Glycated hemoglobin levels, as a reflection of the degree of glycemia, are strongly associated with the risk of cardiovascular disease in diabetics and in the general population. Tight glycemic control, the treatment of dyslipidemia and raised blood pressure, in addition to the use of antiplatelet therapy, all powerfully reduce the risks associated with diabetes. Furthermore, angiotensin-converting enzyme inhibitors might offer additional cardioprotection to diabetics above that provided by blood pressure reduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397648     DOI: 10.1016/s1043-2760(01)00391-5

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  26 in total

1.  Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes.

Authors:  Ibolya Rutkai; Attila Feher; Nora Erdei; Daniel Henrion; Zoltan Papp; Istvan Edes; Akos Koller; Gabor Kaley; Zsolt Bagi
Journal:  Cardiovasc Res       Date:  2009-03-19       Impact factor: 10.787

2.  Use of Metformin in Patients with Kidney and Cardiovascular Diseases.

Authors:  David Klachko; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-04-14       Impact factor: 2.041

Review 3.  The use of ACE inhibitors on diabetic patients without renal disease.

Authors:  Dmitri Kirpichnikov; Nathaniel Winer; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 4.  Role of ACE inhibitors in treating hypertensive diabetic patients.

Authors:  Dmitri Kirpichnikov; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

5.  Possible involvement of IGF-1 receptor and IGF-binding protein in insulin-induced enhancement of noradrenaline response in diabetic rat aorta.

Authors:  Tsuneo Kobayashi; Akihito Kaneda; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

6.  Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.

Authors:  Anitha Varghese; Michael S Yee; Cheuk F Chan; Lindsey A Crowe; Niall G Keenan; Desmond G Johnston; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2009-07-27       Impact factor: 5.364

7.  Inflammation determines the pro-adhesive properties of high extracellular d-glucose in human endothelial cells in vitro and rat microvessels in vivo.

Authors:  Verónica Azcutia; May Abu-Taha; Tania Romacho; Marta Vázquez-Bella; Nuria Matesanz; Francis W Luscinskas; Leocadio Rodríguez-Mañas; María Jesús Sanz; Carlos F Sánchez-Ferrer; Concepción Peiró
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

8.  (-)-Epicatechin-induced recovery of mitochondria from simulated diabetes: Potential role of endothelial nitric oxide synthase.

Authors:  Israel Ramírez-Sánchez; Alonso Rodríguez; Aldo Moreno-Ulloa; Guillermo Ceballos; Francisco Villarreal
Journal:  Diab Vasc Dis Res       Date:  2016-03-18       Impact factor: 3.291

Review 9.  Is taurine beneficial in reducing risk factors for diabetes mellitus?

Authors:  Flavia Franconi; Mauro A S Di Leo; Federico Bennardini; Giovanni Ghirlanda
Journal:  Neurochem Res       Date:  2004-01       Impact factor: 3.996

Review 10.  Role of glomerular filtration rate in controlling blood pressure early in diabetes.

Authors:  Michael W Brands; Hicham Labazi
Journal:  Hypertension       Date:  2008-07-07       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.